Leadership Overview
Sandoz has 10 executives leading key functions including strategy, finance, and operations.
Driven by a commitment to patient access, Sandoz provides high-quality generic medicines and biosimilars across critical therapeutic areas, impacting global health outcomes.
Driven by a commitment to patient access, Sandoz provides high-quality generic medicines and biosimilars across critical therapeutic areas, impacting global health outcomes.
Leadership Roles at Sandoz
Alexandre Jetzer - President & Chief Executive Officer
Alexandre Jetzer, the President & Chief Executive Officer at Sandoz, directs the company's overarching strategy and global operations. Jetzer guides Sandoz's mission to enhance patient access to high-quality medicines worldwide. This leadership encompasses driving innovation in generic drug development and biosimilar production across key therapeutic areas like oncology and immunology. Alexandre Jetzer ensures Sandoz maintains its position as a leader in the pharmaceutical industry by fostering strategic partnerships and optimizing global supply chains. The executive's focus remains on expanding market reach and delivering essential treatments to diverse patient populations. Jetzer's vision propels Sandoz's commitment to affordability and accessibility in healthcare, directly contributing to improved health outcomes on a global scale. Overseeing all business units, Jetzer ensures alignment with Sandoz's core values and long-term growth objectives.
Sameh Ayad - Chief Financial Officer
Sameh Ayad, the Chief Financial Officer at Sandoz, oversees the financial health and strategic fiscal planning for the organization. Ayad directs all financial operations, including budgeting, forecasting, and financial reporting, ensuring robust fiscal management across global markets. This role involves close collaboration with executive leadership to align financial strategies with Sandoz's mission of providing accessible, high-quality generic medicines and biosimilars. Sameh Ayad's responsibilities extend to managing investment strategies and optimizing capital allocation to support research, development, and manufacturing initiatives. The Chief Financial Officer ensures compliance with all financial regulations and drives initiatives for operational efficiency and cost management. Ayad's leadership is critical in maintaining Sandoz's financial stability and supporting its expansion into new therapeutic areas and geographic regions, thereby reinforcing the company's commitment to global healthcare access.
Martin Fournier - Vice President, Finance & Chief Financial Officer
Martin Fournier, the Vice President, Finance & Chief Financial Officer at Sandoz, manages critical financial functions supporting the company's global operations. Fournier directs financial planning and analysis, providing strategic insights to drive business performance and resource allocation. This role involves overseeing budgeting processes, managing financial risks, and ensuring the integrity of financial reporting across various Sandoz divisions. Martin Fournier collaborates with regional finance teams to implement best practices and optimize financial workflows, directly supporting the delivery of high-quality generic medicines and biosimilars. The Vice President, Finance & Chief Financial Officer plays a key part in financial strategy development, contributing to Sandoz's objective of expanding patient access to essential treatments. Fournier's expertise ensures financial discipline and supports sustainable growth initiatives within the pharmaceutical sector.
Mohamed Hashem - Chief Financial Officer, Gulf, Levant & Saudi
Mohamed Hashem, the Chief Financial Officer, Gulf, Levant & Saudi at Sandoz, directs financial strategy and operations within these key Middle Eastern regions. Hashem oversees all fiscal activities, including financial planning, reporting, and compliance, ensuring alignment with Sandoz's global objectives for providing accessible healthcare solutions. This leadership role involves managing regional budgets, optimizing financial performance, and identifying growth opportunities within the Gulf, Levant, and Saudi markets. Mohamed Hashem works closely with local management teams to implement robust financial controls and drive operational efficiencies. The Chief Financial Officer's focus is on strengthening Sandoz's market presence and ensuring the consistent delivery of high-quality generic medicines and biosimilars to patients in these territories. Hashem's financial acumen supports Sandoz's mission to improve health outcomes through affordable treatments.
Sergio Santamaria - Chief Financial Officer, Macc Region
Sergio Santamaria, the Chief Financial Officer, Macc Region at Sandoz, leads financial operations and strategic planning across the Macc region. Santamaria is responsible for overseeing all financial aspects, including budgeting, forecasting, and financial analysis, to support Sandoz's mission of delivering affordable medicines. This executive guides regional financial performance, ensuring compliance with local regulations and international financial standards. Sergio Santamaria collaborates with business leaders to identify and capitalize on market opportunities, driving revenue growth and operational efficiency. The Chief Financial Officer's role is crucial in maintaining financial integrity and supporting the expansion of Sandoz's high-quality generic medicines and biosimilars within the Macc territory. Santamaria's financial stewardship ensures the sustainable delivery of essential healthcare treatments to a broad patient base.
Sam Kwok - Chief Financial Officer (Asia)
Sam Kwok, the Chief Financial Officer (Asia) at Sandoz, directs financial strategy and management across the Asian markets. Kwok oversees all financial operations, including budgeting, financial reporting, and risk management, to support Sandoz's commitment to global healthcare access. This leadership position involves driving financial performance and ensuring compliance with diverse regional regulations. Sam Kwok collaborates with country-specific teams to optimize financial resources and identify strategic growth avenues for generic medicines and biosimilars. The Chief Financial Officer plays a vital role in enhancing Sandoz's market penetration and ensuring the affordability and availability of critical treatments throughout Asia. Kwok's financial expertise underpins the company's objective to improve patient outcomes by providing high-quality, cost-effective pharmaceutical solutions.
Farit Temirgaliev - Chief Financial Officer, Ca & Cau
Farit Temirgaliev, the Chief Financial Officer, Ca & Cau at Sandoz, leads financial strategy and execution within the Canada and Caucasus regions. Temirgaliev manages all financial activities, including fiscal planning, performance analysis, and regulatory compliance, to advance Sandoz's mission of providing accessible healthcare. This role involves optimizing financial resources and driving operational efficiencies to support the delivery of high-quality generic medicines and biosimilars. Farit Temirgaliev collaborates with regional leadership to foster financial discipline and identify strategic growth opportunities. The Chief Financial Officer is instrumental in ensuring the financial stability and market expansion of Sandoz's product portfolio in these territories. Temirgaliev's financial oversight contributes directly to improving patient access to essential treatments.
Monaz Noble - Global Chief Financial Officer, Competency Centre & Country (India)
Monaz Noble, the Global Chief Financial Officer, Competency Centre & Country (India) at Sandoz, directs financial operations for the Indian market and global competency centers. Noble oversees financial planning, reporting, and strategic fiscal management, ensuring alignment with Sandoz's global mission to enhance patient access to medicines. This leadership role involves managing budgets, optimizing financial performance, and implementing robust financial controls across designated areas. Monaz Noble collaborates with international teams to drive efficiency and support the development and delivery of high-quality generic medicines and biosimilars. The Global Chief Financial Officer's expertise is critical in navigating complex financial landscapes and supporting Sandoz's growth objectives in India and globally. Noble's financial acumen strengthens the company's commitment to affordability and quality in healthcare.
Isabella Wanderley - President
Isabella Wanderley, the President at Sandoz, leads strategic initiatives and operational oversight for key business segments. Wanderley drives the company's commitment to expanding access to high-quality generic medicines and biosimilars globally. This executive role involves fostering cross-functional collaboration to ensure efficient product development, manufacturing, and distribution across diverse therapeutic areas. Isabella Wanderley focuses on strengthening Sandoz's market position by identifying and pursuing strategic growth opportunities and partnerships. The President plays a crucial part in upholding Sandoz's mission to make essential treatments more affordable and accessible to patients worldwide. Wanderley's leadership guides the organization toward achieving its long-term vision for global health impact and sustainable business practices.
Biakmawi Phaipi - Team Captain
Biakmawi Phaipi, the Team Captain at Sandoz, leads a dedicated team focused on specific operational objectives within the company's framework. Phaipi directs team efforts towards achieving key performance indicators related to the development, manufacturing, or delivery of Sandoz's high-quality generic medicines and biosimilars. This role involves fostering a collaborative team environment and ensuring efficient execution of assigned tasks. Biakmawi Phaipi works to align team activities with Sandoz's broader mission of enhancing global patient access to essential treatments. The Team Captain's focus is on driving team productivity and ensuring the successful completion of projects that contribute to Sandoz's overall strategic goals. Phaipi's leadership supports the consistent delivery of affordable and effective healthcare solutions.
Explore Leadership Teams in Manufacturing
Gufic Group is a respected player in the pharmaceutical industry, established in 1970, known for its innovative and high-quality pharmaceutical and herbal products, along with a diverse range of APIs. They are recognized as one of India's largest manufacturers of lyophilized injections, offering a variety of products including antibiotics, antifungals, and antiviral treatments. Their extensive network facilitates the supply of these products to major hospital chains and leading medical facilities across India. Gufic is committed to research and development, continuously launching advanced new products while expanding their international footprint.
Company Leadership NY
RK
RA
DR
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) -selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.
Company Leadership
JJ
SK
RF
Sigachi Industries is a leading manufacturer of microcrystalline cellulose and pharmaceutical excipients, catering to the pharmaceutical, cosmetic, food, and nutraceutical industries. The company offers a wide range of products including pre-formulated excipients, thickeners, stabilizers, and dietary fibers. With a strong focus on quality, research, and sustainability, Sigachi aims to provide excellent customer service and innovative solutions to its clients. Their global presence and extensive expertise make them a trusted partner in drug delivery systems and formulation excellence.
Company Leadership LC
AS
OR
Soft gelatin capsule products, liquid preparations, medicinal plasters, ointments, and creams are produced at the Gunung Putri Plant. In producing these products, Gunung Putri Plant implements an Integrated Management System and has obtained ISO 9001:2015, ISO 14001:2015, ISO 45001:2018 and ISO 22000:2018 certificates. Meanwhile, sterile injection products and solid preparations in the form of tablets and capsules are produced at the Citeureup Plant. The Citeureup Plant also implements an Integrated Management System and has obtained ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, and SNI ISO/IEC 17025:2017 certificates. In running the Toll Manufacturing business, Darya-Varia collaborates with an affiliated company, PT Medifarma Laboratories, at the Cimanggis Depok Plant. The Company has been trusted by local business partners and both for the domestic and international markets for the Export & Toll Manufacturing business and conducts technology transfer, lab and pilot trials, stability studies, procurement of raw materials and packaging, and commercial production of high-quality finished goods. Darya-Varia always ensures the quality and safety of each product, so that all of its products are certified halal. All plant facilities owned by Darya-Varia have implemented the halal guarantee system. Blue Sphere Singapore Pte Ltd (BSSPL) owns 92.13% stake in Darya-Varia. For 45 years, Darya-Varia has continued to progress in providing high quality health facilities. Through the mission of "building a healthier Indonesia for everyone one person at a time", Darya-Varia is always committed to providing a variety of quality products with the right strategy for the health of the Indonesian people. DARYA VARIA
Company Leadership CH
Frequently Asked Questions Regarding Sandoz Top Executives and Leadership Team
